基石藥業-B(02616.HK)在2024年ESMO年會上公佈擇捷美®(舒格利單抗注射液)聯合含鉑化療在一線IV期非小細胞肺癌中的長期生存數據
格隆匯9月16日丨基石藥業-B(02616.HK)發佈公吿,舒格利單抗(商品名:擇捷美®)聯合含鉑化療GEMSTONE-302研究的長期治療和生存數據已在2024年歐洲內科腫瘤學會(EMSO)年會公佈。
基石藥業首席執行官、研發總裁兼執行董事楊建新博士表示:“不久前,我們憑藉GEMSTONE302研究預設的PFS和OS分析數據,獲得了歐盟委員會的批准。此次在ESMO公佈的四年隨訪數據,進一步證實了舒格利單抗聯合含鉑化療作為IV期NSCLC一線治療所能帶來的顯着長期獲益。這些數據也充分顯示了舒格利單抗在全球範圍內顯著改善患者預後的潛力。我們將持續擴大這一重要治療方案在全球的可及性,並將繼續致力於實現我們解決未滿足醫療需求的願景。”
GEMSTONE-302研究主要研究者、同濟大學附屬東方醫院周彩存教授表示:“晚期肺癌一線治療的目標是最大限度地改善患者的長期生存獲益。GEMSTONE-302研究結果證實了舒格利單抗聯合含鉑化療作為一線治療能給IV期NSCLC患者帶來長期臨牀獲益,不僅能延長患者生存,還能改善患者生存品質。對於有腦轉移的患者,舒格利單抗聯合療法也同樣顯著延長了PFS和OS,進一步證明這類高風險NSCLC患者也能從舒格利單抗方案中獲益。我們期待這一療法成為NSCLC免疫治療的首選方案之一。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.